Physician profile
Haris Hatic
NPI 1407219041
$3,149.40
in general payments reported to CMS, 2019-2025
37 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.99 · 2022: $411 · 2023: $1,769 · 2024: $656 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.82 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $352.03 | 2022-2023 | Adcetris, Tukysa |
| Novartis Pharmaceuticals Corporation | $209.59 | 2022-2024 | |
| Celgene Corporation | $209.51 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $196.26 | 2022-2025 | |
| Abbvie INC. | $192.70 | 2023-2025 | |
| Janssen Biotech, INC. | $191.59 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Genentech USA, INC. | $168.47 | 2019-2023 | Alecensa, Gavreto, Venclexta |
| Daiichi Sankyo INC. | $162.25 | 2022-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $156.02 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $150.64 | 2022-2025 | Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $145.49 | 2022-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $132.44 | 2023-2024 | Lynparza, Enhertu |
| Mirati Therapeutics, INC. | $102.60 | 2023-2024 | Krazati |
| Eisai INC. | $90.95 | 2022-2023 | |
| Astellas Pharma US INC | $82.07 | 2023-2024 | Padcev, Xtandi |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Hatic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.